pharmaphorum November 12, 2024
23andMe’s big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses.
The company that made its name by providing saliva-based genetic testing for health and ancestry to millions of people around the world made the decision as part of a major restructuring drive that will see 40% of its workforce lose their jobs.
The move into drug discovery was seen as an acknowledgement that the breakneck growth in the genetic testing market was unlikely to be sustainable in the long term, as by its very nature it is a one-shot product without repeat business.
Along with its internal drug development operations, 23andMe has also been developing a business...
Today's Sponsors
Today's Sponsor